##EasyReadMore##

Saturday, November 6, 2010

Weekend Sleuth: We Called It -- The S&P Breaks Higher

The Penny Sleuth Features: Penny Stocks, Options and High-Growth Opportunities!
Penny Sleuth
AuthorsArchivesContactWhitelist Uns     ubscribe
Weekend Sleuth: We Called It –
The S&P Breaks Higher
By Jonas Elmerraji
November 6, 2010


Last Saturday, the outlook was simple: investors are anxious, economic data’s on the horizon, and the S&P 500 (a proxy for the broad market) looks primed to make a move higher.

Sure enough, that’s exactly what happened last week.

The S&P broke above the 200-week moving average, a level that had previously acted as a sort of price ceiling on stocks. Not coincidentally, the move also marked a break to new 52-week highs for stocks, one that should quell at least some of the investor angst that’s been a lightening rod for volatility in the last few trading days.

We’ll want to see stocks consolidate for the next few days to form a base, bleed off “overbought” momentum, and protect against a downward correction. Obviously, my team and I will be watching the market closely next week.

If things play out as expected, November could be a good time to buy penny stocks…


6 Penny Stocks to Own Right Now…

Penny Stock Fortunes is giving away SIX penny stock recommendations to all new subscribers!

But you must hurry because these plays could explode at any time.




How You Can Make Money on New Developments

Last week the Penny Sleuth featured how your can make money on new developments in rare earths and nanotechnology… and a whole lot more. Here’s a recap of last week’s investment insights…

Comment or question about an article? Just click on any article’s title above and join the conversation by leaving a comment...

We’ll be back on next week with more thrilling insights on the on today’s market climate…

Until then, please send me any editorial comments or suggestions at editor@pennysleuth.com.

Have a good weekend,
Jonas Elmerraji
Managing Editor, Penny Sleuth

P.S.: Pharmaceutical stocks are some of the most exciting plays on the market – with huge news-driven rallies and potentially game changing FDA announcements all the time, it’s no surprise this is an area that investors get excited about. Now, our technology expert has released a new report on a tiny company whose drug has shocking potential.

To watch his entire presentation free, just click here. Hurry though, it gets removed from our severs on Thursday, November 11.



Research Reports
The Secret $200 Retirement Blueprint

Investing in Penny Stocks

What Is Technical Trading


Penny Sleuth On Twitter Follow the Penny Sleuth on Twitter, here.
Penny Sleuth On Facebook Become a Facebook Fan of The Penny Sleuth, here.
AGORA FInancial

The Penny Sleuth, a free e-letter, offers independent news and commentary on small cap stocks, options and high growth opportunities. We sent this e-mail to KNUMASSCN@gmail.com because you or someone using your e-mail address subscribed to this service.

Are you having trouble receiving your Penny Sleuth? You can ensure its arrival in your mailbox by: Whitelisting Penny Sleuth.


To end your Penny Sleuth e-mail subscription, click: Unsubscribe.


The Penny Sleuth is your free and independent source for analysis, commentary and news on small cap stocks, options and high growth opportunities. At the Penny Sleuth, we give your our 100% independence pledge. That means that we never receive compensation to talk about any stocks we feature. Our editorial staff never owns a position in any of the stocks we mention at the time of publication. And we only recommend stocks that we come across in our own original research. Our pledge also means that we won't collaborate with companies who don't live up to our independence requirements.

Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

© 2010 Agora Financ ial, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the World Wide Web), in whole or in part, is strictly prohibited without the express written permission of Agora Financial, LLC. 808 Saint Paul Street, Baltimore MD 21202.

No comments:

Not What You Were Looking For? Try a new Google Web Search